Nathan Dolloff to Animals
This is a "connection" page, showing publications Nathan Dolloff has written about Animals.
Connection Strength
0.495
-
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma. Cancer Chemother Pharmacol. 2022 05; 89(5):643-653.
Score: 0.059
-
ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors. Cancer Res. 2020 08 15; 80(16):3279-3291.
Score: 0.052
-
Discovery platform for inhibitors of IgH gene enhancer activity. Cancer Biol Ther. 2019; 20(4):571-581.
Score: 0.047
-
Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019 04; 33(4):1011-1022.
Score: 0.046
-
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Adv Cancer Res. 2015; 127:191-226.
Score: 0.036
-
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 2014 Nov; 28(11):2263-7.
Score: 0.034
-
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012 Nov; 11(11):2321-30.
Score: 0.030
-
Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther. 2011 Aug 15; 12(4):349-56.
Score: 0.028
-
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med. 2011 Jun 08; 3(86):86ra50.
Score: 0.028
-
Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res. 2007 Jan 15; 67(2):555-62.
Score: 0.020
-
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. J Med Chem. 2020 05 28; 63(10):5501-5525.
Score: 0.013
-
Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. Cells. 2019 11 26; 8(12).
Score: 0.012
-
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 01; 88:106271.
Score: 0.012
-
CDK1 stabilizes HIF-1a via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013 Dec 01; 12(23):3689-701.
Score: 0.008
-
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun; 12(6):1140-50.
Score: 0.008
-
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 06; 5(171):171ra17.
Score: 0.008
-
High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. Am J Pathol. 2011 Nov; 179(5):2169-76.
Score: 0.007
-
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
Score: 0.007
-
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
Score: 0.007
-
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle. 2011 Jul 15; 10(14):2331-8.
Score: 0.007
-
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3? and CDK1. Cancer Res. 2011 Aug 01; 71(15):5265-75.
Score: 0.007
-
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle. 2009 Dec 15; 8(24):4168-75.
Score: 0.006
-
The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene. 2009 Jan 22; 28(3):412-21.
Score: 0.006
-
ERK and MDM2 prey on FOXO3a. Nat Cell Biol. 2008 Feb; 10(2):125-6.
Score: 0.005